That's harder
As healthcare professionals, it reminds us that while innovative therapies can transform lives, rigorous monitoring, transparent reporting, and balanced riskbenefit evaluation remain critical
Most people start with a 1 mg weekly dose, but it can go up based on how well blood sugar and weight management are going
The FDA and the EMA are currently evaluating the approval of semaglutide based on results from the SUSTAIN trial, which recruited over 8,000 patients with type 2 diabetes
External resources STEP 1 trial: once-weekly semaglutide in adults with overweight or obesity (NEJM) Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (PMC) Administration errors of compounded semaglutide reported to a poison control center (PubMed) This is not medical advice
However, it has also been noted for its weight loss properties, though its focus remains diabetes management